MK-1775

Catalog No. A10599

MK-1775是一种有效的体外和体内Wee1激酶抑制剂。

Product Citations

Ting-Yu Chang, .et al. A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling, Biomed Pharmacother, 2021, Jun;138:111485 PMID: 33740521
2018, .et al. Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis, FEBS Open Bio, 2018, Jun; 8(6): 1001-1012 PMID: 29928579
Rulina AV, .et al. Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity, Cell Death Dis, 2016, Dec 1;7(12):e2505 PMID: 27906189

Technical details

Catalog Num	A10599
M. Wt	500.6
Formula	C27H32N8O2
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	955365-80-7
Synonyms	MK1775,MK 1775, AZD-1775, AZD1775
SMILES	CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O

Biological Activity

MK-1775是一种有效的体外和体内Wee1激酶抑制剂。

Targets

Wee1 (Cell-free assay)
5.2 nM

Solubility *

In vitro (25°C)	DMSO	71 mg/mL (141.82 mM)
	Water	Insoluble
	Ethanol	9 mg/mL (17.97 mM)
In vivo	2% DMSO+30% PEG 300+5% Tween 80+ddH2O	4 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	19.98 mL	99.88 mL	199.76 mL
0.5 mM	4 mL	19.98 mL	39.95 mL
1 mM	2 mL	9.99 mL	19.98 mL
5 mM	0.4 mL	2 mL	4 mL

*The above data is based on the productmolecular weight 500.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.